NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-08-31
Reading BDX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Becton Dickinson is a stable medical device company growing revenue about 5% yearly. It keeps beating earnings estimates with EPS around $12.6 next year. The company returns cash to shareholders with $2.2 billion in buybacks and dividends. Its valuation is cheap compared to peers with a PE of 11.6 versus 36.5.
Revenue growth could slow below 0% as analysts expect a 9% decline next year. Management is volatile and guidance is soft, which may hurt confidence. The company’s share repurchase progress is mixed and debt repayment plans are uncertain.
The market prices in about 9% revenue decline and the stock trades 29% below our fair value near $220. Our fair value is 26% above the Street median, reflecting more optimism on growth and valuation.
Breaks if: Capital returned falls below $2 billion annually
Breaks if: Debt repayment from cash distribution falls below $1 billion
EPS guidance falls below $12.5 for FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth and margin expansion. The current thesis state is intact, supported by strong recent financial performance, but management execution has been volatile.
The valuation is considered expensive compared to peers, with a premium of 0.51. The market appears to expect continued strong performance, as indicated by a 0.16 expectations gap.
Fundamentals are likely to remain strong in the near term, given the robust earnings quality and recent revenue growth. However, there is a moderate risk due to management's mixed execution on capital allocation priorities.
The long-term thesis hinges on management's ability to advance its growth strategy and successfully execute share repurchases while navigating sector momentum. Key forward scenarios include the impact of sector bellwethers on BDX's performance and potential guidance cuts that could harm credibility.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The successful trial enrollment for hernia prevention mesh supports new product development. Additionally, an earnings beat reinforces the growth strategy and margin expansion. There are no new threats identified that could weaken this outlook.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 0% next year
Complete the spin-off of the Biosciences and Diagnostic Solutions business and combine it with Waters Corporation.
Over the next 1 to 3 years, BDX's performance will depend on management execution and sector dynamics. Not investment advice.
